【大河财立方 记者 陈玉尧】继大普微电子"首单"之后，又一家未盈利企业通过创业板第三套上市标 准，申请A股上市。 12月19日，粤芯半导体技术股份有限公司（以下简称"粤芯半导体"）的创业板IPO申请获深交所受理。 粤芯半导体目前拥有两座12英寸晶圆厂，规划产能合计为8万片/月。未来，将新增建设一条规划产能为 4万片/月的12英寸集成电路数模混合特色工艺生产线。建成后规划产能合计将达到12万片/月。 今年12月10日，粤芯半导体完成A股上市辅导。辅导机构广发证券认为，粤芯半导体已具备成为上市公 司应有的公司治理结构、会计基础工作、内部控制制度。 本次A股IPO，粤芯半导体拟募资75亿元，用于12英寸集成电路模拟特色工艺生产线项目（三期项 目）、特色工艺技术平台研发项目及补充流动资金。 值得注意的是，粤芯半导体目前尚未实现盈利。2022年、2023年、2024年、2025年上半年，该公司分别 亏损10.43亿元、19.17亿元、22.53亿元、12.01亿元，累计亏损达64.14亿元。 粤芯半导体选择的上市标准为《深圳证券交易所创业板股票上市规则（2025年修订）》2.1.2条 之"（三）预计市值不低于50亿元， ...

Core Viewpoint - The introduction of the third listing standard for the ChiNext board marks a significant shift from a "profit-oriented" approach to a "growth-oriented" approach, allowing unprofitable innovative companies to list, thereby enhancing support for technology innovation in the capital market [6][19]. Group 1: Third Listing Standard Requirements - The third listing standard requires a minimum expected market value of 5 billion yuan and a minimum operating income of 300 million yuan in the most recent year, without setting profitability requirements [3][4]. - This standard, which has been in a "not implemented" state since its announcement in February 2023, is now officially activated, allowing unprofitable companies to access the ChiNext board [3][5]. Group 2: Implications of the New Standard - The new standard is expected to facilitate the entry of many early-stage technology companies that have not yet achieved profitability but possess significant potential, which were previously excluded from the A-share market [6]. - The ChiNext board's focus on growth and technological value is anticipated to attract more capital to support innovative enterprises, thus contributing to the development of new productive forces [6]. Group 3: Investment Value of the ChiNext Index - As of June 20, 2025, the ChiNext board has 1,382 listed companies with a total market value of nearly 13 trillion yuan, indicating substantial investment value [7]. - The ChiNext index has shown a cumulative increase of over 100% since its base date, outperforming the CSI 300 index by over 60% during the same period [8]. Group 4: Sector Focus and Valuation - The ChiNext index has a high proportion of emerging industries and high-tech enterprises, focusing on innovation and covering key sectors such as power equipment, pharmaceuticals, telecommunications, and computers [12]. - The current price-to-earnings ratio (PE) of the ChiNext index is 30.38 times, which is at the 10th percentile since its base date, indicating a valuation lower than 90% of its historical levels [16]. Group 5: Opportunities for Investors - The opening of the listing channel for unprofitable technology companies on the ChiNext board presents new opportunities for investors to participate in early-stage investments and share in technological innovations [17][19]. - Investors can diversify their portfolios by increasing exposure to cutting-edge technology sectors, optimizing their investment structure, and potentially benefiting from long-term value investments in innovative companies [18][19].

Core Viewpoint - The enthusiasm of investors in the pharmaceutical primary market has been reignited due to the China Securities Regulatory Commission's announcement of the "1+6" policy measures, which will support unprofitable innovative companies in listing on the Sci-Tech Innovation Board (STAR Market) [1][9]. Group 1: Policy Changes - The introduction of the "new fifth set" listing standards aims to provide a differentiated listing channel for innovative companies that are in the high R&D investment phase but have not yet achieved stable revenue [3][4]. - The "1" in the "1+6" policy refers to the establishment of a Sci-Tech Growth Layer on the STAR Market, which will include all existing and newly registered unprofitable technology companies [3]. - The fifth set of standards will expand its applicability beyond biomedicine to include sectors such as artificial intelligence, commercial aerospace, and low-altitude economy [7]. Group 2: Market Impact - The previous tightening of the STAR Market and the discounting of Hong Kong IPOs led to a significant reduction in investment activity in the pharmaceutical sector, but the reintroduction of the fifth set of standards is expected to enhance investment willingness and risk appetite in the primary market [1][2]. - Since the STAR Market's inception, 20 innovative biopharmaceutical companies have utilized the fifth set of standards for fundraising, with the total investment amount in the biopharmaceutical sector reaching a peak of $34 billion in 2021 [8]. - In 2022, the total investment in the domestic pharmaceutical industry dropped to $15.6 billion, halving compared to the previous year, and further decreased to $10.9 billion in 2023, marking a 30% year-on-year decline [8]. Group 3: Investor Sentiment - The new policies are expected to restore key listing channels for unprofitable pharmaceutical companies, thereby boosting investor confidence and attracting social capital into the biopharmaceutical sector [9]. - There are concerns about potential overheating in the market due to the execution of these policies and the resonance with market sentiment, which could lead to high valuations or share price declines for some unprofitable technology companies post-listing [9].